United States Patent 7,410,978: Trospium Controlled-Release Patent Scope, Claims, Expiration and Competitive Landscape

US Patent 7,410,978 covers once-daily controlled-release trospium chloride formulations designed to release drug in the ileum, colon, or lower gastrointestinal tract. Its strongest claim theme is the combination of multiparticulate delivery technology, delayed or extended release, lower-GI release, and specified trospium pharmacokinetics.

The patent is associated with the development of once-daily trospium chloride extended-release therapy marketed as Sanctura XR. Based on the patent’s filing chronology, its ordinary 20-year patent term would have ended in 2024, subject to any patent-term adjustment or other term events recorded by the USPTO. The patent therefore presents limited current blocking risk as an unexpired US patent, but its claims remain relevant to historical Orange Book coverage, validity analysis, infringement disputes, and related continuation patents.

What does US Patent 7,410,978 protect?

The patent protects pharmaceutical compositions and dosage forms containing trospium chloride in controlled-release particulates. The claimed systems are designed to provide once-daily dosing while maintaining trospium concentrations comparable to twice-daily immediate-release trospium chloride.

The central technical elements are:

Trospium chloride-bearing solid particulates.
At least one release-controlling or enteric polymer.
Extended release, delayed release, or a combination of release profiles.
Release in the ileum, colon, or lower GI tract.
Pharmacokinetic performance within defined trospium concentration, Cmax, Cmin, AUC, or bioavailability ranges.
Reduction of peak-related adverse effects associated with immediate-release trospium.

The claims are directed to compositions and dosage forms, rather than to the trospium molecule itself. They do not broadly claim all trospium chloride products, all once-daily antimuscarinic products, or all controlled-release products without the specified formulation and performance characteristics.

Patent identification and basic data

Field	US 7,410,978
Patent title	Controlled release formulations of trospium chloride
Patent number	US 7,410,978 B2
Technology	Controlled-release and delayed-release trospium chloride
Dosage form	Multiparticulate oral pharmaceutical composition or dosage form
Therapeutic area	Overactive bladder and urinary dysfunction
Core product association	Once-daily trospium chloride extended-release therapy
Issued	August 12, 2008
Ordinary term basis	20 years from the relevant nonprovisional filing date
Nominal term timing	2024, subject to USPTO term adjustment
Regulatory relevance	Historical Orange Book and NDA patent coverage for trospium extended-release therapy

The controlling term date should be confirmed against the USPTO patent record, including any patent-term adjustment, disclaimer, reexamination certificate, or related terminal disclaimer. The patent’s priority and filing records, assignment history, and legal-status data are available through USPTO Patent Center and the published patent record. [1,2]

How are the independent claims structured?

The patent has five principal independent claim groups: claims 1, 17, 18, 20, and 23.

Claim 1: Once-daily formulation with steady-state pharmacokinetics

Claim 1 requires:

A pharmaceutical composition suitable for once-daily administration.
Controlled-release solid trospium-bearing particulates.
At least some release in the lower GI tract.
Blood levels comparable to twice-daily 20 mg immediate-release trospium.
At least one enteric polymer, release-controlling polymer, or combination.

Claim 1 is a product claim with substantial functional limitations. A potentially infringing product would need to satisfy both the structural limitations and the pharmacokinetic requirement. A formulation containing trospium chloride and a release-controlling coating would not necessarily fall within claim 1 unless it also qualifies as a once-daily product and produces the required steady-state blood-level profile.

The phrase "comparable to steady state blood levels" creates a claim-construction issue. The specification and prosecution history would be important in determining whether "comparable" requires a specific statistical or clinical relationship to the 20 mg immediate-release reference regimen.

Claims 17 and 18: Delayed-release lower-GI formulations

Claims 17 and 18 are broader in some respects because they do not expressly require once-daily administration or the claim 1 pharmacokinetic profile.

Claim 17 covers a formulation in which at least part of the trospium chloride:

Is in a delayed-release formulation.
Does not release at a pH below approximately 7.0.
Contains an enteric polymer.

Claim 18 covers a formulation in which at least part of the trospium chloride is released in the lower GI tract and the delayed-release formulation contains an enteric polymer.

These claims focus on the release mechanism and location. They could potentially reach a product that uses delayed release to bypass the stomach and upper small intestine, even if the product does not reproduce every pharmacokinetic range in claims 2 through 7.

Claim 17 is especially dependent on the pH limitation. A formulation that begins meaningful drug release at pH 6.0 or 6.5 may avoid literal infringement if the claim requires no release below approximately pH 7.0. The construction of "does not release" and the permitted meaning of "about" would be material.

Claim 20: Once-daily delivery to the ileum or colon

Claim 20 combines:

Once-daily trospium administration.
Controlled-release trospium particulates.
Release in the ileum, colon, or both.
Steady-state blood levels of approximately 0.5 to 6.0 ng/mL.
Enteric or release-controlling polymer technology.

This claim is narrower than a generic once-daily trospium claim but broader than claims requiring the specific 2.5 to 4.5 ng/mL Cmax range or the 30 to 60 ng/mL·hr AUC range.

Claims 21 and 22 narrow claim 20 by reducing the blood-level range and specifying permitted release configurations.

Claim 23: Once-daily dosage form with therapeutic and tolerability limitations

Claim 23 covers a once-daily dosage form that:

Contains one or more controlled-release particulates.
Releases trospium in the ileum, colon, or both.
Provides effective therapeutic amounts.
Minimizes adverse effects associated with a 40 mg immediate-release formulation.
Contains an enteric polymer, release-controlling polymer, or combination.

This is a mixed structural and functional claim. The formulation structure must be present, but the claim also requires a therapeutic result and reduced adverse effects. Claims 24 through 28 add minimum and maximum concentration limitations. Claims 29 through 31 identify the treated bladder conditions and the adverse effects relevant to the claimed tolerability benefit.

How many patent claims cover trospium pharmacokinetics?

Claims 1 through 7 and claims 20 through 28 contain the principal pharmacokinetic limitations.

Claim group	Pharmacokinetic limitation
Claims 1-3	Steady-state concentration, Cmax and Cmin
Claims 4-5	Steady-state AUC
Claims 6-7	Single-dose relative bioavailability
Claims 20-21	Steady-state blood-level range
Claims 23-28	Therapeutic minimum and toxic maximum concentration concepts

The quantitative ranges are:

Steady-state trospium concentration: approximately 0.5 to 6.0 ng/mL.
Narrower concentration range: approximately 0.5 to 3.0 ng/mL.
Cmax: approximately 2.5 to 4.5 ng/mL.
Cmin: approximately 0.5 to 1.5 ng/mL.
AUC: approximately 30 to 60 ng/mL·hr.
Narrower AUC: approximately 35 to 45 ng/mL·hr.
Single-dose relative bioavailability: approximately 80% to 120%.
Narrower relative bioavailability: approximately 90% to 110%.

A generic or follow-on manufacturer would normally assess these limitations through comparative pharmacokinetic studies. FDA approval of an extended-release generic does not, by itself, establish noninfringement. The legal analysis would depend on the product’s formulation, release testing, label, ANDA certification, and measured pharmacokinetics.

What formulations are protected by US 7,410,978?

The patent expressly covers several release architectures.

Extended-release particulates

Claims 8, 10, and 11 cover extended-release particulates, including formulations releasing approximately 80% of trospium at:

3.5 hours after ingestion; or
4.5 hours after ingestion.

These time-based release limitations are potentially important in formulation comparisons. Dissolution conditions, apparatus, agitation, pH transitions, sampling points, and analytical tolerances would affect the infringement analysis.

Delayed-release particulates

Claims 8, 9, 12, 13, 17, and 18 cover delayed-release systems. Claim 13 identifies release near a GI region with a pH of approximately 7.0. Such a formulation would typically use an enteric coating designed to resist gastric and proximal intestinal conditions before dissolving at a higher pH.

Mixed release systems

Claim 8 covers combinations of:

Extended release and delayed release.
Extended or delayed release with immediate release.
Extended release, delayed release, and immediate release.

This gives the patent coverage over pulsatile or staged delivery designs, provided the other claim limitations are met.

Coated cores and polymer systems

Claim 16 covers trospium-containing cores coated with one or more enteric or release-controlling polymers. Claim 14 lists release-controlling polymers, including:

Acrylic and methacrylic acid ester copolymers.
Ethylcellulose aqueous dispersions.
Hydroxyethyl cellulose.
Hydroxypropyl cellulose.
Hydroxypropyl methylcellulose.
Polyvinylpyrrolidone.
Polyvinylpyrrolidone/vinyl acetate copolymers.
Polyethylene glycols.

Claim 15 lists numerous enteric polymers, including cellulose phthalate derivatives, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, methacrylic acid and methacrylate copolymers, shellac, zein, and related materials.

The polymer list is extensive, but claims 14 and 15 are dependent claims. They do not independently cover every formulation using one of those polymers. The formulation must first satisfy the limitations of the relevant independent claim.

What is the scope of the lower-GI release limitation?

The lower-GI limitation is central to the patent. Claims 1, 18, 20, and 23 identify release in the lower GI tract, with claims 19 and 20 specifically referring to the ileum and colon.

The scope may turn on four questions:

Whether release must occur primarily in the ileum or colon.
Whether partial release in the lower GI tract is sufficient.
Whether the formulation must release a defined percentage of trospium in that region.
Whether in vitro pH dissolution data can establish the in vivo release location.

The claims use language such as "at least a portion" and "at least some." That wording may permit infringement even where only a portion of the drug is delayed to the lower GI tract, provided the remaining claim limitations are satisfied.

A product that releases most trospium in the stomach or proximal small intestine but has a minor enteric fraction may present a fact-intensive analysis. The product’s formulation composition, dissolution profile, in vivo imaging or pharmacokinetic data, and regulatory description would be relevant.

How do claims 29 through 37 affect infringement risk?

Claims 29 through 37 narrow claim 23 by adding therapeutic indication, adverse-effect, and dose limitations.

Claims	Added limitation
29-30	Treatment of urinary frequency, urgency, nocturia, urge incontinence, detrusor instability, urge syndrome, or detrusor hyperreflexia
31	Reduced dry mouth, headache, constipation, dyspepsia, or abdominal pain
32-33	Approximately 25-80 mg or 30-60 mg trospium chloride
34	Approximately 30 mg
35	Approximately 40 mg
36	Approximately 50 mg
37	Approximately 60 mg

Claims 29 and 30 are substantively duplicative. The duplication does not materially expand the scope of claim 23. It may reflect a prosecution or drafting artifact.

The 60 mg limitation in claim 37 is commercially significant because once-daily trospium extended-release products commonly use a 60 mg strength. A 60 mg product would not infringe claim 37 solely because of dose. It would also need to satisfy the incorporated limitations of claim 23, including lower-GI release, controlled-release particulates, and the polymer limitation.

What is the patent strength of US 7,410,978?

The patent has meaningful technical breadth but several potential vulnerability points.

Strengths

Multiple independent claim categories.
Coverage of both extended-release and delayed-release designs.
Explicit protection for ileal and colonic release.
Claims directed to both formulation structure and pharmacokinetic performance.
Polymer claims covering common pharmaceutical coating and matrix materials.
Dose claims reaching the commercially relevant 60 mg strength.
Claims linked to the clinical rationale for once-daily dosing and reduced peak-related side effects.

Potential limitations

Several claims depend on difficult-to-measure in vivo or pharmacokinetic outcomes.
"Comparable," "effective amounts," and "minimizing" may require construction using the specification and prosecution history.
The lower-GI release limitation may be difficult to establish from routine dissolution data alone.
The claims may face prior-art scrutiny from earlier controlled-release, enteric-coated, multiparticulate, and pH-dependent delivery technologies.
Broad polymer lists do not eliminate the need to prove every independent claim element.
The ordinary patent term appears to have ended in 2024, subject to the official USPTO term calculation.

The patent’s commercial importance was likely greater during the period when the branded once-daily product was protected than it is after expiration. Its historical value remains high for evaluating generic entry strategies and related continuation patents.

What was the FDA and Orange Book relevance?

The patent was associated with once-daily trospium chloride extended-release therapy for overactive bladder. The relevant regulatory pathway was an NDA for a new extended-release dosage form rather than an original new molecular entity for trospium chloride.

The Orange Book analysis should distinguish among:

Patents listed against the extended-release NDA.
Patents listed against immediate-release trospium products.
Expired patents.
Unexpired related continuation patents.
FDA-approved labeling that may support a method-of-use or formulation infringement theory.

FDA Orange Book listing does not determine patent validity or enforceability. It does, however, affect ANDA certification obligations. A Paragraph IV certification may trigger statutory litigation under 21 U.S.C. § 355(j)(5)(B)(iii), potentially creating a 30-month stay if the listed patent and procedural requirements are met. [3,4]

Which companies challenged or could challenge the patent?

The likely challengers were generic manufacturers pursuing abbreviated approval for trospium chloride extended-release capsules. The competitive field has included companies active in generic antimuscarinic and extended-release oral dosage products, including large ANDA filers and specialty generic manufacturers.

A definitive list of Paragraph IV challengers, litigation actions, settlements, and launch dates requires the relevant FDA Orange Book historical records, ANDA litigation complaints, and court dockets. Those records should be read together because an Orange Book listing alone does not prove that a Paragraph IV challenge was filed, and a patent expiration date alone does not establish the timing of commercial generic entry.

What generic entry risks exist after patent expiration?

After expiration of the patent, the principal barriers shift from patent exclusivity to formulation development and regulatory approval.

Key risks include:

Demonstrating bioequivalence to the reference extended-release product.
Matching the reference product’s multiparticulate release profile.
Establishing acceptable food-effect performance.
Controlling dose dumping and variability.
Reproducing lower-GI or delayed-release behavior without using the same polymer combination.
Avoiding unexpired continuation or improvement patents.
Assessing pediatric exclusivity, pediatric extensions, or other regulatory term adjustments.
Managing manufacturing complexity and supply-chain costs.

A generic product can avoid literal infringement by using a different release mechanism, different polymer system, different dose, or different pharmacokinetic profile. That strategy may increase development risk if the alternative product no longer meets the FDA’s bioequivalence requirements.

How does US 7,410,978 compare with immediate-release trospium?

Issue	Immediate-release trospium	Controlled-release technology in US 7,410,978
Typical administration concept	Twice daily	Once daily
Reference regimen in claim 1	20 mg twice daily	PK comparable to the reference regimen
Release site	Primarily upper GI absorption environment	At least part released in ileum, colon, or lower GI
Dosage technology	Immediate-release tablet	Multiparticulate controlled-release system
Peak exposure	Higher peak-related tolerability concern	Lower or controlled peak exposure is a claimed objective
Main patent issue	Less directly covered by this patent	Core subject of claims 1, 17, 18, 20 and 23
Commercial formulation risk	Lower manufacturing complexity	Higher coating, dissolution, and process-control burden

The patent is not a basic composition-of-matter patent for trospium chloride. Its value depends on the controlled-release product architecture and its resulting clinical pharmacokinetics.

What licensing and settlement issues matter?

Potential licensing or settlement agreements would be relevant if they:

Granted a generic manufacturer an authorized-launch date.
Carved out specific indications or dosage strengths.
Settled Paragraph IV litigation.
Licensed polymer, coating, or multiparticulate manufacturing technology.
Addressed related continuation patents rather than US 7,410,978 itself.

A patent settlement does not necessarily establish validity. It may reflect commercial timing, litigation cost, launch economics, or risk allocation. The operative agreements and court orders are required to determine whether a settlement affected entry timing or product scope.

Key Takeaways

US 7,410,978 targets once-daily controlled-release trospium chloride, not trospium chloride generally.
The principal inventive combination is multiparticulate trospium delivery with enteric or release-controlling polymers and lower-GI release.
Claims 1, 20, and 23 combine formulation structure with pharmacokinetic or therapeutic-performance limitations.
Claims 17 and 18 provide broader delayed-release coverage but remain tied to enteric polymers and lower-pH resistance or lower-GI release.
Claims 10 through 13 are important for specific extended-release timing and mixed-release configurations.
The 60 mg dose claims are commercially relevant but do not create standalone protection without the limitations of claim 23.
Claims 29 and 30 are duplicative and do not materially expand claim scope.
The patent’s ordinary 20-year term appears to have ended in 2024, subject to the official USPTO term calculation.
Current generic risk depends more on related unexpired patents, FDA approval status, and formulation bioequivalence than on US 7,410,978 alone.
A complete freedom-to-operate review must include continuation patents, Orange Book history, ANDA certifications, litigation records, and any patent-term adjustment.

FAQs

Does US 7,410,978 cover all 60 mg trospium products?

No. Claim 37 covers a 60 mg dosage only through the limitations inherited from claim 23. A 60 mg product must also use controlled-release particulates, release at least part of the trospium in the ileum or colon, use the specified polymer technology, and satisfy the functional limitations.

Can a product avoid the patent by using an extended-release matrix instead of coated pellets?

Possibly, but not automatically. Claim 14 includes several release-controlling polymers, and claim 1 is not limited exclusively to coated pellets. The matrix product would need to be compared element by element against the asserted claim.

Does FDA approval of a trospium generic prove that US 7,410,978 is invalid?

No. FDA approval and patent validity are separate issues. An ANDA applicant may rely on a Paragraph IV certification, a patent expiration certification, a section viii statement, or other regulatory position.

Does release at pH 6.8 infringe the pH 7.0 limitation?

The answer depends on claim construction, testing methodology, and the meaning of "about." A formulation that releases at pH 6.8 could raise an infringement issue, but the result cannot be determined from the claim text alone.

Are biosimilars relevant to this patent?

No. Trospium chloride is a small-molecule active ingredient. Competitive products would proceed through the generic drug pathway, principally under ANDA procedures, rather than through the biosimilar pathway under the Public Health Service Act.

References

United States Patent and Trademark Office. (2008). Controlled release formulations of trospium chloride, U.S. Patent No. 7,410,978 B2.
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	493981	⤷ Start Trial
Australia	2004289223	⤷ Start Trial
Canada	2537103	⤷ Start Trial
Germany	602004030931	⤷ Start Trial
Denmark	2210605	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,410,978

Summary for Patent: 7,410,978